Acceptance of the extracare program by Beta interferon-treated patients with multiple sclerosis: results of the explore study.

J Neurosci Nurs

Matthias Freidel, MD, is a Neurologist and Psychiatrist at Neurologische Praxis, Kaltenkirchen, Germany. Sonja Ortler, PhD, is an Employee at Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany. Questions or comments about this article may be directed to Alexander Fuchs, PhD, at He is an Employee at Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany. Sabine Seibert, PhD, is an Employee at Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany. Katrin Schuh, PhD, is an Employee at Clinical Research Neuroscience, Novartis Pharma GmbH, Nuremberg, Germany.

Published: February 2015

Background: To gain full benefit from disease-modifying therapies such as interferon β-1b, patients with multiple sclerosis (MS) need to adhere to treatment in the long term. Treatment adherence requires high patient satisfaction with treatment and care.

Objectives: Our aim was to evaluate the satisfaction of patients with MS receiving interferon β-1b Extavia with the patient care program Extracare. Efficacy and safety of treatment were evaluated as secondary objectives.

Methods: In this prospective, noninterventional 1-year study, data on the satisfaction of 174 patients with MS with Extracare were obtained by questionnaires. Disability and symptom severity as well as patients' reported activity limitations, quality of life, and fatigue were recorded.

Results: We observed high levels of patients' satisfaction with MS nurses, telephonic care, and information provided by Extracare (values ≤ 1.53 on a Likert scale ranging from 1 [very good] to 6 [insufficient]). Patient reported quality of life (Patient Reported Indices for MS QoL) improved from 11.82 ± 11.36 at baseline to 9.74 ± 10.94 at the end of the study (p = .02), whereas clinical parameters of disease progression remained unchanged. Rate of adverse events was as expected.

Conclusions: This study provides the basis for further improvements of care programs to increase treatment adherence of patients with MS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334305PMC
http://dx.doi.org/10.1097/JNN.0000000000000100DOI Listing

Publication Analysis

Top Keywords

patients multiple
8
multiple sclerosis
8
interferon β-1b
8
treatment adherence
8
quality life
8
patient reported
8
patients
5
treatment
5
acceptance extracare
4
extracare program
4

Similar Publications

Investigating Smartphone-Based Sensing Features for Depression Severity Prediction: Observation Study.

J Med Internet Res

January 2025

Department of Clinical Psychology and Psychotherapy, Institute of Psychology and Education, Ulm University, Ulm, Germany.

Background: Unobtrusively collected objective sensor data from everyday devices like smartphones provide a novel paradigm to infer mental health symptoms. This process, called smart sensing, allows a fine-grained assessment of various features (eg, time spent at home based on the GPS sensor). Based on its prevalence and impact, depression is a promising target for smart sensing.

View Article and Find Full Text PDF

Genomic data on from the African continent are currently lacking, resulting in the region being under-represented in global analyses of infection (CDI) epidemiology. For the first time in Nigeria, we utilized whole-genome sequencing and phylogenetic tools to compare isolates from diarrhoeic human patients (=142), livestock (=38), poultry manure (=5) and dogs (=9) in the same geographic area (Makurdi, north-central Nigeria) and relate them to the global population. In addition, selected isolates were tested for antimicrobial susceptibility (=33) and characterized by PCR ribotyping (=53).

View Article and Find Full Text PDF

A comprehensive insights of cancer immunotherapy resistance.

Med Oncol

January 2025

Department of In Vivo Pharmacology, TCG Lifesciences Pvt. Ltd, BN 7, Sector V, Salt Lake City, Kolkata, West Bengal, 700091, India.

Cancer is a major global health issue that is usually treated with multiple therapies, such as chemotherapy and targeted therapies like immunotherapy. Immunotherapy is a new and alternative approach to treating various types of cancer that are difficult to treat with other methods. Although immune checkpoint inhibitors have shown promise for long-term efficacy, they have limited effectiveness in common cancer types such as breast, prostate, and lung.

View Article and Find Full Text PDF

Kaposi Sarcoma (KS) is a frequently aggressive malignancy caused by Kaposi sarcoma herpesvirus (KSHV/HHV-8). People with immunodeficiencies, including HIV, are at increased risk for developing KS, but our understanding of the contributions of the cellular genome to KS pathogenesis remains limited. To determine if there are cellular genetic alterations in KS that might provide biological or therapeutic insights, we performed whole exome sequencing on 78 KS tumors and matched normal control skin from 59 adults with KS (46 with HIV-associated KS and 13 with HIV-negative KS) receiving treatment at the Uganda Cancer Institute in Kampala, Uganda.

View Article and Find Full Text PDF

We present a case of a patient with an intrathecal pump who experienced an unrecognized partial pocket fill, leading to an atypical opioid withdrawal characterized by akathisia. A 57-year-old female with multiple myeloma presented to an emergency department with new-onset akathisia requiring admission. Eight weeks prior, her intrathecal pump was refilled with morphine, bupivacaine, and ziconotide.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!